Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Johnson & Johnson Underwhelms With Modest EPS Forecast


However you slice it, J&J's prospect of earnings growth looks bleak as economic and competitive "headwinds" continue.

Johnson & Johnson (JNJ) followed Eli Lilly (LLY) Tuesday as the latest big drug maker to announce a lower-than-expected earnings forecast for this year.

The company said it expects earnings per share of $5.05 to $5.15 excluding costs of a major acquisition.

That estimate badly missed Wall Street expectations ($5.20) and would represent a measly gain on the "adjusted" EPS the company just reported ($5). The news sent the company's stock down before markets opened today. The shares recovered, trading up less than 1% to $65.16 midday.

The company cited a stronger dollar, higher costs and pricing pressure as reason for the temperate forecast. Those challenges are on top of generic competition, a lagging US economy and two years of recalls, government investigations and sanctions on the company's over-the-counter drug business.

J&J's CEO William Weldon calls them "headwinds."

This is the pharmaceutical industry in 2012. Lilly blamed its weak outlook on rapid erosion of anti-psychotic drug Zyprexa, which began facing generic competition late last year.

J&J has some unique problems, including legal costs related to illegal marketing of its own anti-psychotic drug Risperdal and expenses related to product liability and the recall fiasco. (Those and other costs contributed to an almost 90% plunge in fourth-quarter income.)

And, to be sure, the company isn't a pure pharmaceutical maker. It's much more diverse with a sizable medical device business that's about to get a whole lot bigger with the planned $20 billion takeover of Synthes. But J&J faces pressures seen in other big drug companies, most notably the patent expirations. J&J sales last year were hurt by generic competition for Levaquin, a treatment for bacterial infections, for instance. The US economy is hurting J&J's orthopedics business as some patients put off elective surgeries.

While the various costs contributed to lower net income in 2011, sales rose 5.6% to $65 billion. US sales, however, declined almost 2%, the company said. (Sales in this country dropped more than 3% in the fourth quarter.)

"This weaker-than-expected operational quarter could confirm investor fears of a protracted and broad economic slowdown," says Leerink Swann analyst Rick Wise. He rates the stock a buy with a $70 price target.

In the past six months, J&J's stock has declined almost 3%, which lags the share performance of rivals Pfizer (PFE), Merck (MRK), Bristol-Myers Squibb (BMY) and Lilly, which have all recorded gains in that period.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos